Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9ENA

Lysosomal glucocerebrosidase in complex with a stabilizing nanobody

Summary for 9ENA
Entry DOI10.2210/pdb9ena/pdb
DescriptorGlucosylceramidase, Chains: B, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (7 entities in total)
Functional Keywordsglucosidase, glucosyltransferase, lipid metabolism, gcase, nanobody, complex, allosteric, stabilizer, hydrolase
Biological sourceHomo sapiens (human)
More
Total number of polymer chains2
Total formula weight72950.21
Authors
Dal Maso, T.,Versees, W. (deposition date: 2024-03-12, release date: 2025-06-04)
Primary citationDal Maso, T.,Sinisgalli, C.,Zilio, G.,Franzin, E.,Tessari, I.,Pardon, E.,Steyaert, J.,Ballet, S.,Greggio, E.,Versees, W.,Plotegher, N.
Developing nanobodies as allosteric molecular chaperones of glucocerebrosidase function.
Nat Commun, 16:4890-4890, 2025
Cited by
PubMed Abstract: The enzyme glucocerebrosidase (GCase) catalyses the hydrolysis of glucosylceramide to glucose and ceramide within lysosomes. Homozygous or compound heterozygous mutations in the GCase-encoding GBA1 gene cause the lysosomal storage disorder Gaucher disease, while heterozygous and homozygous mutations are the most frequent genetic risk factor for Parkinson's disease. These mutations commonly affect GCase stability, trafficking or activity. Here, we report the development and characterization of nanobodies (Nbs) targeting and acting as molecular chaperones for GCase. We identify several Nb families that bind with nanomolar affinity to GCase. Based on biochemical characterization, we group the Nbs in two classes: Nbs that improve the activity of the enzyme and Nbs that increase GCase stability in vitro. A selection of the most promising Nbs is shown to improve GCase function in cell models and positively impact the activity of the N370S mutant GCase. These results lay the foundation for the development of new therapeutic routes.
PubMed: 40425544
DOI: 10.1038/s41467-025-60134-4
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.7 Å)
Structure validation

246905

PDB entries from 2025-12-31

PDB statisticsPDBj update infoContact PDBjnumon